Duchenne muscular dystrophy

被引:798
作者
Duan, Dongsheng [1 ,2 ,3 ,4 ]
Goemans, Nathalie [5 ]
Takeda, Shin'ichi [6 ]
Mercuri, Eugenio [7 ,8 ]
Aartsma-Rus, Annemieke [9 ]
机构
[1] Univ Missouri, Sch Med, Dept Mol Microbiol & Immunol, Columbia, MO 65212 USA
[2] Univ Missouri, Sch Med, Dept Neurol, Columbia, MO USA
[3] Univ Missouri, Coll Vet Med, Dept Biomed Sci, Columbia, MO USA
[4] Univ Missouri, Coll Engn, Dept Biomed Biol & Chem Engn, Columbia, MO USA
[5] Univ Hosp Leuven, Dept Child Neurol, Leuven, Belgium
[6] Natl Ctr Neurol & Psychiat, Tokyo, Japan
[7] Policlin Gemelli, Ctr Clin Nemo, Rome, Italy
[8] Catholic Univ, Peadiat Neurol, Rome, Italy
[9] Leiden Univ, Med Ctr, Dept Human Genet, Leiden, Netherlands
基金
美国国家卫生研究院;
关键词
QUALITY-OF-LIFE; MUSCLE STEM-CELLS; SKELETAL-MUSCLE; NITRIC-OXIDE; GLYCOPROTEIN COMPLEX; NONSENSE MUTATION; GENE-THERAPY; MOUSE MODEL; DMD GENE; OXIDATIVE STRESS;
D O I
10.1038/s41572-021-00248-3
中图分类号
R5 [内科学];
学科分类号
100201 [内科学];
摘要
Duchenne muscular dystrophy is a severe, progressive, muscle-wasting disease that leads to difficulties with movement and, eventually, to the need for assisted ventilation and premature death. The disease is caused by mutations in DMD (encoding dystrophin) that abolish the production of dystrophin in muscle. Muscles without dystrophin are more sensitive to damage, resulting in progressive loss of muscle tissue and function, in addition to cardiomyopathy. Recent studies have greatly deepened our understanding of the primary and secondary pathogenetic mechanisms. Guidelines for the multidisciplinary care for Duchenne muscular dystrophy that address obtaining a genetic diagnosis and managing the various aspects of the disease have been established. In addition, a number of therapies that aim to restore the missing dystrophin protein or address secondary pathology have received regulatory approval and many others are in clinical development. Duchenne muscular dystrophy is an X-linked progressive, muscle-wasting disease that manifests in childhood as difficulties with movement. This Primer by Aartsma-Rus and colleagues discusses the clinical presentation, epidemiology, pathophysiology, genetic diagnosis and treatment of this disorder.
引用
收藏
页数:19
相关论文
共 219 条
[41]
MYOSTATIN INHIBITOR ACE-031 TREATMENT OF AMBULATORY BOYS WITH DUCHENNE MUSCULAR DYSTROPHY: RESULTS OF A RANDOMIZED, PLACEBO- CONTROLLED CLINICAL TRIAL [J].
Campbell, Craig ;
Mcmillan, Hugh J. ;
Mah, Jean K. ;
Tarnopolsky, Mark ;
Selby, Kathryn ;
Mcclure, Ty ;
Wilson, Dawn M. ;
Sherman, Matthew L. ;
Escolar, Diana ;
Attie, Kenneth M. .
MUSCLE & NERVE, 2017, 55 (04) :458-464
[42]
Ryanodine channel complex stabilizer compound S48168/ARM210 as a disease modifier in dystrophin-deficient mdx mice: proof-of-concept study and independent validation of efficacy [J].
Capogrosso, Roberta Francesca ;
Mantuano, Paola ;
Uaesoontrachoon, Kitipong ;
Cozzoli, Anna ;
Giustino, Arcangela ;
Dow, Todd ;
Srinivassane, Sadish ;
Filipovic, Marina ;
Bell, Christina ;
Vandermeulen, Jack ;
Massari, Ada Maria ;
De Bellis, Michela ;
Conte, Elena ;
Pierno, Sabata ;
Camerino, Giulia Maria ;
Liantonio, Antonella ;
Nagaraju, Kanneboyina ;
De Luca, Annamaria .
FASEB JOURNAL, 2018, 32 (02) :1025-1043
[43]
"The Social Network" and Muscular Dystrophies: The Lesson Learnt about the Niche Environment as a Target for Therapeutic Strategies [J].
Cappellari, Ornella ;
Mantuano, Paola ;
De Luca, Annamaria .
CELLS, 2020, 9 (07)
[44]
CASKEY CT, 1980, CLIN GENET, V18, P329
[45]
CHAMBERLAIN JS, 1992, JAMA-J AM MED ASSOC, V267, P2609
[46]
The Dystrophin Glycoprotein Complex Regulates the Epigenetic Activation of Muscle Stem Cell Commitment [J].
Chang, Natasha C. ;
Sincennes, Marie-Claude ;
Chevalier, Fabien P. ;
Brun, Caroline E. ;
Lacaria, Melanie ;
Segales, Jessica ;
Munoz-Canoves, Pura ;
Ming, Hong ;
Rudnicki, Michael A. .
CELL STEM CELL, 2018, 22 (05) :755-+
[47]
DYSTROPHIN GENE TRANSCRIBED FROM DIFFERENT PROMOTERS IN NEURONAL AND GLIAL-CELLS [J].
CHELLY, J ;
HAMARD, G ;
KOULAKOFF, A ;
KAPLAN, JC ;
KAHN, A ;
BERWALDNETTER, Y .
NATURE, 1990, 344 (6261) :64-65
[48]
DENOVO DNA MICRODELETION IN A GIRL WITH TURNER SYNDROME AND DUCHENNE MUSCULAR-DYSTROPHY [J].
CHELLY, J ;
MARLHENS, F ;
LEMAREC, B ;
JEANPIERRE, M ;
LAMBERT, M ;
HAMARD, G ;
DUTRILLAUX, B ;
KAPLAN, JC .
HUMAN GENETICS, 1986, 74 (02) :193-196
[49]
Correction of muscular dystrophies by CRISPR gene editing [J].
Chemello, Francesco ;
Bassel-Duby, Rhonda ;
Olson, Eric N. .
JOURNAL OF CLINICAL INVESTIGATION, 2020, 130 (06) :2766-2776
[50]
Molecular analysis of the dystrophin gene in 407 Chinese patients with Duchenne/Becker muscular dystrophy by the combination of multiplex ligation-dependent probe amplification and Sanger sequencing [J].
Chen, Wan-Jin ;
Lin, Qi-Fang ;
Zhang, Qi-Jie ;
He, Jin ;
Liu, Xin-Yi ;
Lin, Min-Ting ;
Murong, Shen-Xing ;
Liou, Chia-Wei ;
Wang, Ning .
CLINICA CHIMICA ACTA, 2013, 423 :35-38